Retinal signs and 20-year cognitive decline in the Atherosclerosis Risk in Communities Study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 3, 2017
- Accepted in final form December 19, 2017
- First Published February 28, 2018.
Article Versions
- Previous version (February 28, 2018 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Jennifer A. Deal, PhD,
- A. Richey Sharrett, MD, DrPH,
- Andreea M. Rawlings, MS, PhD,
- Rebecca F. Gottesman, MD, PhD,
- Karen Bandeen-Roche, PhD,
- Marilyn Albert, PhD,
- David Knopman, MD,
- Elizabeth Selvin, PhD, MPH,
- Bruce A. Wasserman, MD,
- Barbara Klein, MD, MPH and
- Ronald Klein, MD, MPH
- Jennifer A. Deal, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- A. Richey Sharrett, MD, DrPH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NHLBI HL 96812, Co-Investigator 2010-2014
Professor, Johns Hopkins Bloomberg School of Public Health
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andreea M. Rawlings, MS, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rebecca F. Gottesman, MD, PhD,
Member of DSMB for "Sail-on" study, (PI: V. Urrutia), funded via Genentech (no compensation received).
NONE
Cardiothoracic Surgery Symposium; funds for travel (reimbursement)
Neurology, Associate Editor, 2015-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Florbetapir isotope (18F-AV-45) provided for investigator-initiated research by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
National Institutes of Health/ National Institute on Aging. 1R01AG040282, Principal Investigator, 9/2011-8/2021 RF1 AG050745, Multiple Principal Investigator, 4/2016-3/2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Karen Bandeen-Roche, PhD,
3 nonprofit advisory boards. Yearly service. Honarium < $1000.00 per case.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) MedImmune LLC. (2) Geisinger Health Systems.
(1) P50AG005146 (Albert) 04/01/10 ? 03/31/20 NIH/NIA; Role: Co-Investigator; Data Core Director Johns Hopkins Alzheimer's Disease Research Center (ADRC) The aims are to coordinate and integrate all aspects of data management, provide statistical support and expert statistical consultation for projects, and develop novel methods of analysis for the ADRC. (2) 2P30AG021334 (Walston/Bandeen Roche) 07/01/13 ? 06/30/18 NIH/NIA; Role: Director of the Biostatistics Core Older Americans Independence Center The Center is dedicated to research to determine the causes and treatments for frailty in older adults. (3) UL1TR001079 (Ford) 09/26/13 ? 04/30/18 NIH/NCRR; Role: Co-Investigator; Deputy Director Institutional Clinical and Translational Science Award Goals are to enhance the process and benefits of clinical and translational research by bringing together the diverse resources of the JHMI and creating a new model for carrying out scientific research (4) 1UH2AG056933-01 (Walston) 07/01/17 ? 06/30/22 NIH/NIA; Role: Co-Investigator Characterizing Resiliencies to Physical Stressors in Older Adults: A Dynamical Physiological Systems Approach In phase 1 of this study, data will be generated to characterize age-related changes in physical resiliencies and their determinants and outcomes. In phase 2, measures of resiliency will be constructed, validated and assessed for clinical value, and biologic mechanisms determining specific resiliencies will be investigated. (5) 1R03AG053743-01 (Xue) 09/01/16 ? 05/31/18 NIH/NIA; Role: Co-Investigator Physical Frailty and Cognitive Impairment: Intersection, Measurement & Etiologies The proposal aims to study the natural history of the development of physical frailty and cognitive impairment, and propose and validate a joint phenotype of physical frailty and cognitive impairment. (6) P30AG048773 (Roth) 09/30/14 ? 05/31/19 NIH/NIA; Role: Co-Investigator Roybal Centers for Translational Research on Aging - Strengthening Informal Support Resources with Strategic Methodological Advances Provide leadership and critical infrastructure to stimulate, facilitate, and extend innovative research in the behavioral and social sciences for older adults. Unifying emphases are on understanding and strengthening the informal support resources of vulnerable older adult populations, and methodological innovations. (7) P01AG009973 (Gallagher) 08/15/15-05/31/20 NIH/NIA; Role: Co-Investigator; Data Core Leader Cognition and Hippocampal/Cortical Systems in Aging This multi-component research program studies a rodent model of naturally occurring variation in cognitive aging. It aims to understand the neurobiological basis of impairment and preservation of brain function. (8) 1R01AG050560-01 (Walston) 09/01/16-05/31/18 NIH/NIA; Role: Co-Investigator Enhancing Mobility in Older Adults by Treating Chronic Inflammation: Pilot Phase Few options have been tested for ameliorating mobility declines in older adults through treatment of chronic inflammation (CI). We propose preliminary work needed to develop an inflammatory phenotype that can be utilized in future intervention studies on effects of reducing low-grade CI on mobility limitations in older adults. (9)R03AG048541 (Xue) 07/01/14 ? 06/30/17 NIH/NIA; Role: Co-Investigator Frailty Assessment: Matching Simplification Efforts to Clinical Aims This study contrasts two commonly used assessment tools for identifying frail old adults and evaluates potential ways to simplify the tools for clinical practice. (10) R01 HL096812 (Coresh) 09/01/15 - 06/30/17 NIH/NHLBI; Role: Co-Investigator 1 of 5 Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS) The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS) aims to elucidate factors underlying ethnic disparities in dementia burden and provide scientific basis for prevention strategies. (11) 113000-0615 (Bandeen-Roche) 09/23/14 ? 05/31/17 KKI sub; Role: Principal Investigator Intellectual and Development Disabilities The Biostatistics Component of our IDDRC?s Clinical Translational Core supports a broad range of projects focused on expanded understanding of developmental disorders. (12)ME-1303-5946 (Bridges) 07/1/13 ? 11/30/16 PCORI: Role: Co-Investigator Advancing stated-preference methods for measuring the preferences of patients with type 2 diabetes This project aims to advance and disseminate methods for patient and stakeholder engagement in patient-centered outcomes research. We address methodological gaps associated with stated-preferences methods.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marilyn Albert, PhD,
Eli Lilly
NONE
Center for Vital Longevity, Univ Texas - honorarium
NONE
NONE
NONE
NONE
Consultant to: Dana Foundation
NONE
NONE
NONE
Avid Radiopharmaceuticals - research grant
Grants from NIH: NIH/NIA, U19-AG033655 (PI) 2009 - present NIH/NIA, P50 AG005146 (PI) 2009 - present NIH/NIA, R01 AG048349 (Co-PI) 2015 - present NIH/NINDS UH2 NS100588(Co-PI) 2016 - present
Massachusetts General Hospital, Harvard Medical School
Alzheimer's Association and Fidelity Biosciences
NONE
NONE
NONE
NONE
NONE
NONE
- David Knopman, MD,
Consultant Bluefield project (frontotemporal dementia) (ongoing); Lundbeck Pharmaceuticals (Sept 2013 to August 2017); DIAN study DSMB (Sept 2013 ongoing).
NONE
(1) Lectures, Behavioral Neurology Conference, Hyderabad, India April 2016
Associate Editor Neurology, ended October 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Tau Rx clinical trial funded by TAURX (site PI) (2) A4 clinical trial partially funded by Lilly (site PI) (3) Biogen Alzheimer Study (site PI)
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer?s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elizabeth Selvin, PhD, MPH,
NONE
NONE
NONE
Clinical Chemistry
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
FNIH, NKF, NIH/NIDDK grants R01 DK089174, K24 DK106414, R01 HL134320, R01 DK108784
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bruce A. Wasserman, MD,
NONE
NONE
Speaker honoraria: Abington Hospital - Jefferson Health
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
R01AG054491, PI, NIH/NIA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barbara Klein, MD, MPH and
Pfizer Scientific Advisory Committee
NONE
NONE
(1) Ophthalmic Epidemiology, Editorial advisory board, 1994-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Institutes of Health EY006594, HL69979, AG11099, AG021917, AG12100
(1) University of Wisconsin-Madison
(1) Retina Research Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Ronald Klein, MD, MPH
Astra-Zeneca 1999-present, advisor
NONE
NONE
Ophthalmology Editorial Advisory Board, 1985-present
NONE
NONE
NONE
Pfizer, consultant, 2007-present Eli Lilly, consultant, 2004-present Novartis, consultant, 2008 Genentech, consultant, 2008 Comentis, data monitoring safety committee member, 2008-2009 Allergan, consultant, 2008 Merck, consultant, 2008
NONE
NONE
NONE
NONE
NIH-NEI, PI, 2 U10 EY006594-21A1 09/01/08 - 06/30/13 NIH-NEI, PI, 1 R01 HL6997 08/15/08 - 8/14/2016 NIH, NEI, PI, 1 R01 EY016379, PI 07/01/05 ? 06/30/09 NIH/DK, PI, 1 R01 DK073217-01 08/20/06 ? 07/31/09 NIH, PI, N01-AG-12100 09/30/02 - 09/29/12
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Epidemiology (J.A.D., A.R.S., A.M.R., R.F.G., E.S.), Neurology (R.F.G., M.A.), Biostatistics (K.B.-R.), and Radiology and Radiological Sciences (B.A.W.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.K.), Mayo Clinic, Rochester, MN; and Department of Ophthalmology and Visual Sciences (B.K., R.K.), University of Wisconsin School of Medicine and Public Health, Madison.
- Correspondence
Dr. Deal jdeal1{at}jhu.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.